ATE340565T1 - Pharmazeutische darreichungsform zur mukosalen verabreichung - Google Patents

Pharmazeutische darreichungsform zur mukosalen verabreichung

Info

Publication number
ATE340565T1
ATE340565T1 AT03710927T AT03710927T ATE340565T1 AT E340565 T1 ATE340565 T1 AT E340565T1 AT 03710927 T AT03710927 T AT 03710927T AT 03710927 T AT03710927 T AT 03710927T AT E340565 T1 ATE340565 T1 AT E340565T1
Authority
AT
Austria
Prior art keywords
dosage form
pharmaceutical dosage
mucosal administration
tablet
subject
Prior art date
Application number
AT03710927T
Other languages
English (en)
Inventor
Alice C Martino
Steven A Pierman
Robert M Noack
Nancy Britten
Original Assignee
Pharmacia Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Corp filed Critical Pharmacia Corp
Application granted granted Critical
Publication of ATE340565T1 publication Critical patent/ATE340565T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Reproductive Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT03710927T 2002-02-07 2003-02-06 Pharmazeutische darreichungsform zur mukosalen verabreichung ATE340565T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US35570302P 2002-02-07 2002-02-07

Publications (1)

Publication Number Publication Date
ATE340565T1 true ATE340565T1 (de) 2006-10-15

Family

ID=27734551

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03710927T ATE340565T1 (de) 2002-02-07 2003-02-06 Pharmazeutische darreichungsform zur mukosalen verabreichung

Country Status (21)

Country Link
US (1) US20030235617A1 (de)
EP (1) EP1471890B1 (de)
JP (1) JP2005519924A (de)
KR (1) KR100666520B1 (de)
CN (1) CN100346832C (de)
AT (1) ATE340565T1 (de)
AU (1) AU2003215110B2 (de)
BR (1) BR0307473A (de)
CA (1) CA2474190A1 (de)
CO (1) CO5611096A2 (de)
DE (1) DE60308647T2 (de)
DK (1) DK1471890T3 (de)
ES (1) ES2271542T3 (de)
MX (1) MXPA04007728A (de)
NO (1) NO20043723L (de)
NZ (1) NZ534340A (de)
PL (1) PL372290A1 (de)
PT (1) PT1471890E (de)
RU (1) RU2285520C2 (de)
WO (1) WO2003066029A2 (de)
ZA (1) ZA200405614B (de)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
BRPI0302736B8 (pt) * 2003-06-02 2021-05-25 Ems S/A composição farmacêutica a base de cetorolaco ou de um de seus sais farmaceuticamente aceitáveis para uso sublingual
SE0401031D0 (sv) 2004-04-22 2004-04-22 Duocort Ab A new glucocorticoid replacement therapy
WO2006085497A1 (ja) * 2005-02-09 2006-08-17 Kissei Pharmaceutical Co., Ltd. 口腔内崩壊錠
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
CN106727271B (zh) * 2006-01-06 2020-02-14 阿塞尔Rx制药有限公司 小体积口腔经粘膜剂型
US8513299B2 (en) 2006-05-19 2013-08-20 Pernix Sleep, Inc. Methods of using low-dose doxepin for the improvement of sleep
US20100179214A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin trans isomers and isomeric mixtures and methods of using the same to treat sleep disorders
US20090042971A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Method of using low-dose doxepin for the improvement of sleep
US20090042972A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
WO2007142811A2 (en) * 2006-05-19 2007-12-13 Somaxon Pharmaceuticals, Inc. Low dose doxepin formulations, including buccal, sublingual and fastmelt formulations, and uses of the same to treat insomnia
WO2007136845A2 (en) 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. Low-dose doxepin for treatment of sleep disorders in elderly patients
WO2007136741A2 (en) * 2006-05-19 2007-11-29 Somaxon Pharmaceuticals, Inc. N-desmethyl-doxepin and methods of using the same to treat sleep disorders
US20100179215A1 (en) 2006-05-19 2010-07-15 Somaxon Pharmaceuticals, Inc. Doxepin isomers and isomeric mixtures and methods of using the same to treat sleep disorders
DE102006027796A1 (de) * 2006-06-16 2007-12-20 Lts Lohmann Therapie-Systeme Ag Estrogen-Gestagen-Kombinationen
MX2008016569A (es) * 2006-07-07 2009-01-30 Teva Pharma Composiciones solidas que contienen tadalafil y al menos un portador.
CA2693992C (en) * 2006-07-20 2017-01-31 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
US20080182890A1 (en) * 2006-10-04 2008-07-31 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
WO2008052139A2 (en) 2006-10-25 2008-05-02 Somaxon Pharmaceuticals, Inc. Ultra low dose doxepin and methods of using the same to treat sleep disorders
US20110077200A1 (en) * 2006-12-06 2011-03-31 Somaxon Pharmaceuticals, Inc. Combination therapy using low-dose doxepin for the improvement of sleep
CA2721133C (en) 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
KR20100012867A (ko) * 2007-04-25 2010-02-08 테바 파마슈티컬 인더스트리즈 리미티드 타다라필을 포함하는 고체 제형
DE102007028869A1 (de) * 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US20090036414A1 (en) * 2007-08-02 2009-02-05 Mutual Pharmaceutical Company, Inc. Mesalamine Formulations
WO2010005922A1 (en) * 2008-07-07 2010-01-14 Fasgen, Inc. Novel compounds, pharmaceutical compositions containing same, methods of use for same, and methods for preparing same
CN101757623B (zh) * 2008-10-09 2013-12-04 北京德众万全药物技术开发有限公司 一种5-ht受体激动剂固体药物组合物
TWI455733B (zh) 2009-03-30 2014-10-11 Toray Industries 口腔內崩壞性被覆錠劑
US20110268809A1 (en) 2010-04-28 2011-11-03 Paul Andrew Brinkley Nicotine-Containing Pharmaceutical Compositions
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
EA015250B9 (ru) * 2010-11-19 2013-10-30 Тева Фармасьютикал Индастриз, Лтд. Таблетка силденафила, обеспечивающая модифицированную фармакокинетику, и способ ее изготовления
US20120195954A1 (en) * 2011-02-02 2012-08-02 Roxiticus Health Products, Llc Method of Reducing Appetite
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
BR112014026439B1 (pt) * 2012-04-27 2022-05-31 Merck Patent Gmbh Formulação farmacêutica sob a forma de um comprimido revestido, e seu processo de preparação
PT3417862T (pt) * 2012-07-27 2021-08-06 Neurodyn Life Sciences Inc Biodisponibilidade cerebral da galantamina melhorada através de formulações selecionadas e administração transmucosal de pró-fármacos lipofílicos
US20140255452A1 (en) 2013-03-11 2014-09-11 Niconovum Usa, Inc. Method and apparatus for differentiating oral pouch products
CA3042642A1 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015122477A1 (ja) * 2014-02-12 2015-08-20 沢井製薬株式会社 フィルムコーティングされた口腔内崩壊錠
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
AU2015290098B2 (en) 2014-07-17 2018-11-01 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
JP6529822B2 (ja) * 2015-05-22 2019-06-12 東和薬品株式会社 トリプタン系化合物を含有する口腔内崩壊錠
US20170165252A1 (en) 2015-12-10 2017-06-15 Niconovum Usa Inc. Protein-enriched therapeutic composition
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
DK3807260T3 (da) 2018-06-15 2024-10-14 Reynolds Tobacco Co R Oprensning af nikotin
CN113613630A (zh) * 2019-03-01 2021-11-05 因斯格尼斯疗法有限公司 地匹福林口腔崩解片剂制剂
US12377112B2 (en) 2019-04-17 2025-08-05 Compass Pathfinder Limited Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
CN111499545B (zh) * 2020-04-27 2022-05-03 武汉英纳氏药业有限公司 一种对氨基取代苯酚类化合物的制备方法
WO2022069956A1 (en) 2020-09-29 2022-04-07 Millicent Pharma Limited Orodispersible formulations
CN116457021A (zh) 2020-11-25 2023-07-18 英特维特国际股份有限公司 通过氟尼辛的颊部施用治疗疼痛的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0181966A1 (de) * 1984-11-13 1986-05-28 Gist-Brocades N.V. Pressdragierte dispergierbare Tabletten
US5273975A (en) * 1989-06-09 1993-12-28 The Upjohn Company Heterocyclic amines having central nervous system activity
EP0743850B1 (de) * 1994-01-27 1999-10-06 The Board Of Regents Of The University Of Oklahoma Schnell auflösende orale darreichungsform
ES2143049T3 (es) * 1994-04-22 2000-05-01 Pentech Pharmaceuticals Inc Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.
US6121276A (en) * 1994-04-22 2000-09-19 Pentech Pharmaceuticals, Inc. Apomorphine-containing dosage forms for ameliorating male erectile dysfunction
US5624677A (en) * 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
US5888534A (en) * 1995-06-13 1999-03-30 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
GB9616672D0 (en) * 1996-08-08 1996-09-25 Scherer Ltd R P Pharmaceutical compositions
US5939091A (en) * 1997-05-20 1999-08-17 Warner Lambert Company Method for making fast-melt tablets
AU747099B2 (en) * 1997-10-31 2002-05-09 Pharmacia Corporation Gellan gum tablet coating
EP1086140B1 (de) * 1998-06-10 2003-01-22 CP Kelco ApS Zusammensetzung auf basis von modifiziertem gellangummi, verfahren zu dessen herstellung und seine verwendung
WO2000007584A2 (en) * 1998-08-04 2000-02-17 Wisconsin Alumni Research Foundation Method of reducing retinal ganglion cell degeneration
US5994363A (en) * 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6552024B1 (en) * 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
DE60310039T2 (de) * 2002-02-07 2007-04-05 Pharmacia Corp. Pharmazeutische Tabletten

Also Published As

Publication number Publication date
RU2004124057A (ru) 2005-04-20
NO20043723L (no) 2004-09-06
DK1471890T3 (da) 2007-01-08
MXPA04007728A (es) 2004-11-10
JP2005519924A (ja) 2005-07-07
ES2271542T3 (es) 2007-04-16
CO5611096A2 (es) 2006-02-28
RU2285520C2 (ru) 2006-10-20
DE60308647T2 (de) 2007-08-09
CN1627938A (zh) 2005-06-15
WO2003066029A3 (en) 2003-10-16
NZ534340A (en) 2006-04-28
EP1471890B1 (de) 2006-09-27
BR0307473A (pt) 2004-11-09
KR20040083503A (ko) 2004-10-02
ZA200405614B (en) 2005-06-27
US20030235617A1 (en) 2003-12-25
CN100346832C (zh) 2007-11-07
PT1471890E (pt) 2007-01-31
DE60308647D1 (de) 2006-11-09
AU2003215110A1 (en) 2003-09-02
WO2003066029A2 (en) 2003-08-14
EP1471890A2 (de) 2004-11-03
AU2003215110B2 (en) 2007-11-29
PL372290A1 (en) 2005-07-11
CA2474190A1 (en) 2003-08-14
KR100666520B1 (ko) 2007-01-11

Similar Documents

Publication Publication Date Title
ATE340565T1 (de) Pharmazeutische darreichungsform zur mukosalen verabreichung
DK1419765T3 (da) Fremgangsmåde til fremstilling af analgetiske tabletter omfattende et brusende reaktant-par til administration over mundslimhinden
MXPA02004235A (es) Dosificacion de farmacos a traves de la mucosa oral usando una solucion solida.
Ghosh et al. Drug delivery to the oral cavity: molecules to market
TW200505498A (en) Sugar-free oral transmucosal solid dosage forms and uses thereof
ATE138562T1 (de) Transmukosale dosisform
IL196425A0 (en) Pharmaceutical compositions containing ibuprofen and famotidine
EP2444072A3 (de) Nichtmukoadhäsive Filmdosierungsformen
NO20071795L (no) Octenidin-inneholdende tabletter anvendt mot betennelsessykdommer i munn og svelg
WO2007012019A3 (en) Medicaments containing famotidine and ibuprofen and administration of same
AP2003002763A0 (en) Controlled release formulations for oral administration
ATE531361T1 (de) Neue pharmazeutische dosierform und herstellungsverfahren
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
JP2005525329A5 (de)
RU2004129284A (ru) Амброксол для лечения болей в полости рта и глотки
PL1778209T3 (pl) Sposoby i kompozycje do doustnego dostarczania FTS
Bhoi et al. An Innovative approach for Oral Drug Delivery System
MY145885A (en) Controlled release formulations for oral administration

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1471890

Country of ref document: EP

REN Ceased due to non-payment of the annual fee